Search results
Showing 61 to 75 of 185 results for prostate cancer
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
NG12/05 Question Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed...
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
investigations for CPG 3 prostate cancer: What is the diagnostic accuracy of staging investigations for CPG 3 prostate...
clinically and cost-effective pathway for diagnosing clinically significant prostate cancer? Any explanatory notes(if applicable) Why...
clinically and cost-effective pathway for diagnosing clinically significant prostate cancer? Any explanatory notes(if applicable) Why...
Past technology appraisal appeals and decisions
GreenLight XPS for treating benign prostatic hyperplasia (HTG650)
Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for HTG171Show all sections
Sections for HTG171
next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal...
advanced prostate cancer? Any explanatory notes(if applicable) Source guidance details Comes from guidance Prostate cancer:...
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
unnecessary bowel cancer referrals A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel...
using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate...
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.